TRIUS THERAPEUTICS INC

Reported by

KPCB PBD ASSOCIATES, LLC

FORM 3/A

(Amended Statement of Beneficial Ownership)

Filed 08/04/10 for the Period Ending 08/02/10

Address	6310 NANCY RIDGE DR SUITE 105 SAN DIEGO, CA 92121
Telephone	858-452-0370
CIK	0001356857
Symbol	TSRX
SIC Code	2834 - Pharmaceutical Preparations
Fiscal Year	12/31

http://www.edgar-online.com
© Copyright 2010, EDGAR Online, Inc. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use.

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0104
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Date of Event Requiring Statement (MM/DD/YYYY)	3. Issuer Name **and** Ticker or Trading Symbol
KPCB PBD Associates, LLC	**8/2/2010**	**Trius Therapeutics Inc [TRSX]**
(Last) (First) (Middle) **C/O KLEINER PERKINS CAUFIELD & BYERS, 2750 SAND HILL ROAD**	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director ___ **X** ___ 10% Owner _____ Officer (give title below) _____ Other (specify below)	
(Street) **MENLO PARK, CA 94025** (City) (State) (Zip)	5. If Amendment, Date Original Filed (MM/DD/YYYY) **8/2/2010**	6. Individual or Joint/Group Filing (Check Applicable Line) _ **X** _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (*e.g.* , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B Preferred Stock	(1)	(2)	**Common Stock**	**9078000**	(3)	**I**	**See Footnote** (4)
Series B Preferred Stock	(1)	(2)	**Common Stock**	**54000**	(3)	**I**	**See Footnote** (5)
8% Convertible Promissory Notes	(6)	(6)	**Common Stock**	**498394**	(6)	**I**	**See Footnote** (4)
8% Convertible Promissory Notes	(6)	(6)	**Common Stock**	**2965**	(6)	**I**	**See Footnote** (5)

Explanation of Responses:

(1) Immediately exercisable.

(2) Shares do not expire.

(3) Upon consummation of its initial public offering, every 8.6 shares of the issuer's Series B Preferred Stock will be converted into 1 share of Common Stock.

(4) Shares are held directly by KPCB Pandemic and Bio Defense Fund, LLC of which the Reporting Person is the Managing Member. The Reporting Person disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein.

(5) Shares are held directly by KPCB PBD Founders Fund, LLC of which the Reporting Person is the Managing Member. The Reporting Person disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein.

(6) Principal and accrued interest will convert upon the Issuers initial public offering into shares of Common Stock at a conversion price of 87.5% of the per share price of the Common Stock sold in the Issuer's initial public offering anticipated to occur on August 6, 2010 at $5.00 per share.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KPCB PBD Associates, LLC **C/O KLEINER PERKINS CAUFIELD & BYERS** **2750 SAND HILL ROAD** **MENLO PARK, CA 94025**		**X**		

Signatures

/s/ Theodore E. Schlein, Manager — ** Signature of Reporting Person

8/3/2010 — Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

***** If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

****** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.